Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone for cannabis addiction
NL-OMON28347Phase 3Withdrawn
- Sponsor
- Centrum Maliebaan
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cannabis use disorder (CUD) comparing Naltrexone + usual cognitive-behavioral treatment with Placebo + usual cognitive-behavioral treatment (2 arms). Primary endpoints: Cannabis craving, Cannabis use and 4 more. Planned start Jul 2010; status: withdrawn.
02
Drugs
naltrexone
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NL-OMON28347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28347.